Fig. 2

Correlations of TIDE status with clinicopathological and molecular features in the BC patients. A Associations of TIDE scores with clinicopathological and molecular features in BC patients. Columns represented samples ranked by TIDE scores from low to high (top row), and rows represent clinicopathological and molecular features associated with TIDE scores. B–J) Comparisons of TIDE scores with subgroups of survival status (OS_Status) (B), pathological TNM stage (pTNM) (C–E), histological grade (hGrage) (F), histological subtype (hSubtype) (G), TCGA mRNA subtype (H), tumor mutation load (TMB) (I) and microsatellite instability (MSI) (J). LUMI, Luminal-infiltrated; LUMP, Luminal-papillary; LUM, Luminal; BASS, Basal-squamous; NEU, Neuronal. K, L Correlations of TIDE scores with neoantigen load (K) and stemness index (mRNAsi) (L) in BC patients. M–P Kaplan–Meier (K–M) analysis demonstrated a correlation of the TIDE scores with the prognosis of BC patients from TCGA-BLCA (M), GSE31684 (N), GSE154261 (O) and IMvigor210 (P) datasets. OS, overall survival; RFS, recurrence-free survival. Dashed line: median survival time. Color range: 95% confidence interval (CI). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance